JP2020513839A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513839A5 JP2020513839A5 JP2019558994A JP2019558994A JP2020513839A5 JP 2020513839 A5 JP2020513839 A5 JP 2020513839A5 JP 2019558994 A JP2019558994 A JP 2019558994A JP 2019558994 A JP2019558994 A JP 2019558994A JP 2020513839 A5 JP2020513839 A5 JP 2020513839A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- seq
- optionally
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762445976P | 2017-01-13 | 2017-01-13 | |
| US62/445,976 | 2017-01-13 | ||
| PCT/US2018/013551 WO2018132695A1 (en) | 2017-01-13 | 2018-01-12 | Chimeric antigen receptors targeting tim-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513839A JP2020513839A (ja) | 2020-05-21 |
| JP2020513839A5 true JP2020513839A5 (enExample) | 2021-02-25 |
| JP7303749B2 JP7303749B2 (ja) | 2023-07-05 |
Family
ID=62840504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558994A Active JP7303749B2 (ja) | 2017-01-13 | 2018-01-12 | Ｔｉｍ－１を標的とするキメラ抗原受容体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11541076B2 (enExample) |
| EP (1) | EP3568416A4 (enExample) |
| JP (1) | JP7303749B2 (enExample) |
| CN (1) | CN110494451B (enExample) |
| WO (1) | WO2018132695A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3035080A1 (en) | 2016-09-27 | 2018-04-05 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| JP7286658B2 (ja) | 2017-09-26 | 2023-06-05 | セロ・セラピューティクス・インコーポレイテッド | キメラエンガルフメント受容体分子および使用方法 |
| AU2019243154A1 (en) | 2018-03-28 | 2020-10-01 | Cero Therapeutics, Inc. | Cellular immunotherapy compositions and uses thereof |
| EP3774906A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| WO2019222579A1 (en) * | 2018-05-17 | 2019-11-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
| CN110615842B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含共刺激受体的嵌合抗原受体及应用 |
| IL280329B2 (en) * | 2018-08-02 | 2024-09-01 | Kite Pharma Inc | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| AU2019327913A1 (en) * | 2018-08-29 | 2021-03-18 | Nanjing Legend Biotech Co., Ltd. | Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof |
| EP3902838A4 (en) | 2018-12-26 | 2022-12-21 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| CA3139319A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of polypeptides and chimeric antigen receptors via hinge domains |
| JP2022541320A (ja) * | 2019-07-24 | 2022-09-22 | エウレカ セラピューティクス インコーポレイテッド | キメラ抗原受容体ｔ細胞及びその使用 |
| CN112079934B (zh) * | 2019-12-17 | 2021-01-29 | 合源生物科技(天津)有限公司 | 一种靶向cd19的嵌合抗原受体及其用途 |
| WO2021130535A2 (en) * | 2019-12-28 | 2021-07-01 | Shanghai Cell Therapy Group Company Co., Ltd. | Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules |
| JP2023514232A (ja) * | 2020-02-14 | 2023-04-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ２活性化を伴うキメラ抗原受容体 |
| GB202004371D0 (en) * | 2020-03-26 | 2020-05-13 | Glaxosmithkline Ip Dev Ltd | CAR constructs |
| CR20220540A (es) * | 2020-03-31 | 2022-12-07 | Chugai Pharmaceutical Co Ltd | Moléculas de union al antígeno multiespecíficas dirigidas a claudina-6 y sus usos |
| US12264190B2 (en) * | 2020-04-24 | 2025-04-01 | Astrazeneca Ab | Compositions and methods of treating cancer with chimeric antigen receptors |
| CN115884781A (zh) * | 2020-06-09 | 2023-03-31 | 杭州领知医药科技有限公司 | 用于增强免疫应答的组合物和方法 |
| CN112063588A (zh) * | 2020-08-13 | 2020-12-11 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| JP2023546067A (ja) * | 2020-10-13 | 2023-11-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ｍＲＮＡ治療剤のためのＴ細胞のインビボ標的化 |
| CN114149505B (zh) * | 2021-01-12 | 2022-11-04 | 北京门罗生物科技有限公司 | 治疗b细胞相关疾病的免疫细胞、制备方法及其应用 |
| CN114807044B (zh) * | 2021-04-30 | 2023-09-08 | 四川大学华西医院 | 一种具有高nkt细胞比例的car-cik细胞制备方法及应用 |
| WO2022248602A1 (en) * | 2021-05-25 | 2022-12-01 | Institut Curie | Myeloid cells overexpressing bcl2 |
| CN115521917A (zh) * | 2021-06-25 | 2022-12-27 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
| CN113583122B (zh) * | 2021-07-29 | 2023-08-29 | 武汉华美生物工程有限公司 | 抗人sema4d抗体及其制备方法和应用 |
| CN115322257B (zh) * | 2021-08-16 | 2023-05-30 | 上海优替济生生物医药有限公司 | Bcma靶向抗体、嵌合抗原受体及其应用 |
| CN116426483B (zh) * | 2021-12-30 | 2024-02-23 | 南京紫珑生物科技有限公司 | Cd258蛋白在免疫治疗中的应用 |
| CN115974976B (zh) * | 2022-11-23 | 2024-06-04 | 华中科技大学 | 拮抗多肽及用于制备抗急性肾损伤药物的应用 |
| US20250092362A1 (en) * | 2023-09-15 | 2025-03-20 | Terumo Bct, Inc. | System And Methods For Producing Chimeric Antigen Receptor Cells |
| CN119409822B (zh) * | 2024-11-01 | 2026-02-17 | 中国科学技术大学 | 抗体或其抗原结合片段及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ530457A (en) * | 2001-06-01 | 2007-12-21 | Biogen Idec Inc | Molecules and methods for inhibiting shedding of KIM-1 |
| US20050014687A1 (en) | 2002-03-19 | 2005-01-20 | Anderson David W. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| ES2557769T3 (es) | 2003-03-19 | 2016-01-28 | Amgen Fremont Inc. | Anticuerpos contra el antígeno del dominio de inmunoglobulina de células T y el dominio 1 de mucina (TIM-1) y usos de los mismos |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| EP1957115B8 (en) * | 2005-11-10 | 2014-03-05 | Celldex Therapeutics, Inc. | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013078089A1 (en) * | 2011-11-22 | 2013-05-30 | Biogen Idec Ma Inc. | Anti-tim-1 antibodies and uses thereof |
| KR102264290B1 (ko) | 2012-08-20 | 2021-06-10 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법을 위한 방법 및 조성물 |
| US10836998B2 (en) | 2014-02-14 | 2020-11-17 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| EP2939690A1 (en) * | 2014-04-29 | 2015-11-04 | Medizinische Hochschule Hannover | Vaccine |
| WO2016062898A1 (en) * | 2014-10-24 | 2016-04-28 | Bcrt Holding Bv | T cell-based immunotherapeutics |
| WO2016115482A1 (en) * | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) * | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| WO2016168595A1 (en) | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
-
2018
- 2018-01-12 JP JP2019558994A patent/JP7303749B2/ja active Active
- 2018-01-12 EP EP18739365.7A patent/EP3568416A4/en active Pending
- 2018-01-12 CN CN201880011066.7A patent/CN110494451B/zh active Active
- 2018-01-12 WO PCT/US2018/013551 patent/WO2018132695A1/en not_active Ceased
- 2018-01-12 US US16/477,609 patent/US11541076B2/en active Active
-
2022
- 2022-12-12 US US18/064,514 patent/US20230355673A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513839A5 (enExample) | ||
| US11932698B2 (en) | Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof | |
| US12304935B2 (en) | Immunomodulatory polypeptides and related compositions and methods | |
| IL295604A (en) | Methods of making chimeric antigen receptor-expressing cells | |
| HRP20251135T1 (hr) | Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2017522879A5 (enExample) | ||
| JP2018538339A5 (enExample) | ||
| US20200268797A1 (en) | Gamma delta t cells and uses thereof | |
| JP2017522880A5 (enExample) | ||
| KR20230084470A (ko) | 면역 세포 기능의 향상 | |
| CN117683139A (zh) | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 | |
| AU2025279733A1 (en) | Rituximab-resistant chimeric antigen receptors and uses thereof | |
| KR20220130100A (ko) | 키메라 t 세포 지속성 향상을 위한 akt 억제제 | |
| US20240033357A1 (en) | Chimeric antigen receptors and uses thereof | |
| US20210355442A1 (en) | Gamma delta t cells and uses thereof | |
| JP2022513164A (ja) | 胎盤由来同種ｃａｒ－ｔ細胞およびその使用 | |
| US20240150456A1 (en) | Engineered immune cells and uses thereof | |
| JPWO2023278520A5 (enExample) | ||
| KR20260013488A (ko) | 면역 이펙터 세포 및 이의 용도 | |
| JPWO2021186397A5 (enExample) | ||
| AU2024300134A1 (en) | Fusion protein for treating diseases related to cd20 | |
| KR20260022392A (ko) | 융합 단백질 및 그의 의학적 용도 | |
| EP4715044A1 (en) | Cell treatment product preparation process and use thereof | |
| IL313388A (en) | Chimeric antigen receptor-modified cells for the treatment of CLDN6-expressing cancer |